Immunological and metabolic responses of patients with history of antibody-induced beef insulin resistance to treatment with beef, pork, human, and sulfated beef insulin.
OBJECTIVE
We evaluated immunological and metabolic responses during therapy with beef (B), pork (P), human (H, rDNA), and sulfated beef (SB) insulins in patients with insulin-antibody-mediated insulin resistance.


METHODS
A randomized double-blind sequential crossover study was performed with each insulin administered for 56 days unless dose reached 200 U/day or allergy developed. Participants were 26 individuals with history of B-P insulin dosage greater than or equal to 200 U/day and insulin binding capacities greater than 0.216 nM (30 mU/ml serum). Twenty-one participants completed the study. Insulin dosage/day, fasting plasma glucose, percentage HbA1, insulin antibody binding capacity (IABC), bound insulin (BI), percentage binding of 125I-labeled B, P, and H insulins, and receptor inhibition factor (RIF) were assessed.


RESULTS
Mean insulin dosage (U/day) was significantly greater on B (88.9) than on P (29.2), H (29.4), or SB (29.6). On B, dosage increased in 12 individuals and reached 200 U/day in 6 individuals. Mean fasting plasma glucose (12.1 mM) and HbA1 (11%) were significantly higher on B than on P, H, and SB. Mean IABC, bound insulin, RIF, and percentage of B, P, and H bound were significantly higher on B than on P, H, and SB. Prolonged treatment with SB before entry into the study (greater than 5 wk) resulted in a blunted anamnestic response to B insulin.


CONCLUSIONS
Rechallenge with B results in anamnestic immunological response and deterioration of metabolic control. SB, H, and P insulins have equivalent effects in patients with insulin antibody-mediated immunologic resistance.
Davidson
J K
JK
Department of Medicine, Indiana University School of Medicine, Indianapolis.
Fineberg
S E
SE
De Meyts
P
P
Fineberg
N S
NS
Galloway
J A
JA
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002417:Cattle; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000032:analysis; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D007330:Insulin Antibodies; D007333:Insulin Resistance; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013552:Swine
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007328:Insulin; D007330:Insulin Antibodies; D011994:Recombinant Proteins; C076568:sulfated beef insulin